About Us


Syntimmune approaches areas of high unmet medical need in a unique way.

Syntimmune focuses on areas of science that are well understood and extensively researched. We seek new treatments that build on these areas of scientific consensus and broad applicability.

In the case of our lead drug candidate, SYNT001, both the cellular pathway and the specific molecular target have been studied extensively for more than 25 years, spearheaded by the groundbreaking research of the scientific team behind Syntimmune.

In an industry that often places a premium on novelty, Syntimmune understands that creating real value comes from helping patients who are suffering with diseases for which current treatments are inadequate or nonexistent.



Richard Blumberg, M.D.

Scientific Founder, Director and Chairman of the Scientific Advisory Board

Laurence Blumberg, M.D.

Business Founder


Jean-Paul Kress, M.D.

President & Chief Executive Officer

Jodie Morrison

Chief Operating Officer

Asti Goyal

Vice President, Corporate Strategy

Adam Hansard

Vice President, Business Operations

Stephanie Haller

Vice President, Clinical

Nicole Lousey

Vice President, Program Management

Leslie Stolz, Ph.D.

Vice President, Regulatory Strategy

Andreas Woppmann, Ph.D.

Executive Vice President, Pharmaceutical Development, Technical Operations & Global Quality

Board of Directors

Laurence Blumberg, M.D.


Burt Adelman, M.D.

Senior advisor, Syntimmune

Seth Harrison, M.D.

Apple Tree Partners

Sam Hall, Ph.D.

Apple Tree Partners

Aaron Kantoff

Apple Tree Partners

Scientific Advisory Board

Richard Blumberg, M.D.

Chairman, Scientific Advisory Board
Harvard Medical School

Wayne Lencer, M.D.

Harvard Medical School

Inger Sandlie, Ph.D.

University of Oslo

Derry Roopenian, Ph.D.

The Jackson Laboratory

Alan Bitonti, Ph.D.

Senior Advisor


ATP logo-01